Peregrine Pharmaceuticals Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (47)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Peregrine Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Peregrine Pharmaceuticals. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “7” cancer drugs in clinical pipeline and majority of them are in preclinical phase. There is 1 cancer drug by Peregrine Pharmaceuticals which is commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Peregrine Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Peregrine Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Peregrine Pharmaceuticals. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “7” cancer drugs in clinical pipeline and majority of them are in preclinical phase. There is 1 cancer drug by Peregrine Pharmaceuticals which is commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Peregrine Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Peregrine Pharmaceuticals

  1.1 Business Overview

  1.2 Peregrine Pharmaceuticals Cancer Pipeline Overview

 

2. Peregrine Pharmaceuticals Cancer Drugs in Preclinical Phase

  2.1 Bavituximab

  2.2 Anti-Phosphatidylserine Monoclonal Antibodies - Peregrine Pharmaceuticals

  2.3 Anti-Phosphatidylserine Monoclonal Antibodies - Affitech/Peregrine Pharmaceuticals

  2.4 Vascular Disruptive Agents - Targa Therapeutics

 

3. Peregrine Pharmaceuticals Cancer Drugs in Phase-0

  3.1 PGN 650 I-124

 

4. Peregrine Pharmaceuticals Cancer Drugs in Phase-II/III

  4.1 Bevacizumab Biosimilar - International Biotech Center Generium

 

5. Peregrine Pharmaceuticals Cancer Drugs in Phase-III

  5.1 Durvalumab

  5.2 Marketed Peregrine Corporation Cancer Clinical Insight by Indication & Phase

  5.3 Iodine I 131 Derlotuximab Biotin (Cotara)

 

6. No Development Reported in Cancer Drugs in Clinical Pipeline

  6.1 Tumour Necrosis Therapeutics - Peregrine/Stason

 

7. Discontinued in Cancer Drugs in Clinical Pipeline

  7.1 Monoclonal antibody LYM-1-I-131

  7.2 Vasopermeation Enhancement Agents - Peregrine

  7.3 Immunocytokine Fusion Proteins - Peregrine/Biotecnol

  7.4 Monoclonal Antibody CLL-1

  7.5 Monoclonal Antibody LYM-2


Figure 1-1: Peregrine Pharmaceuticals Cancer Pipeline by Phase (%)

Figure 1-2: Peregrine Pharmaceuticals Cancer Pipeline by Phase (Number)

Figure 1-3: Peregrine Pharmaceuticals Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Peregrine Pharmaceuticals Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)